Eyck BM, van Lanschot JJB, Hulshof M, van der Wilk BJ, Shapiro J, van Hagen P, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial. J Clin Oncol. 2021;39:1995–2004.

Article  CAS  PubMed  Google Scholar 

Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.

Article  PubMed  Google Scholar 

Sugimura K, Yamasaki M, Yasuda T, Yano M, Hirao M, Fujitani K, et al. Long-term results of a randomized controlled trial comparing neoadjuvant Adriamycin, cisplatin, and 5-fluorouracil vs docetaxel, cisplatin, and 5-fluorouracil followed by surgery for esophageal cancer (OGSG1003). Ann Gastroenterol Surg. 2021;5:75–82.

Article  PubMed  Google Scholar 

Kitagawa Y, Ishihara R, Ishikawa H, Ito Y, Oyama T, Oyama T, et al. Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: part 2. Esophagus. 2023;20:373–89.

Article  PubMed  PubMed Central  Google Scholar 

Kitagawa Y, Ishihara R, Ishikawa H, Ito Y, Oyama T, Oyama T, et al. Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1. Esophagus. 2023;20:343–72.

Article  PubMed  PubMed Central  Google Scholar 

Watanabe M, Toh Y, Ishihara R, Kono K, Matsubara H, Murakami K, et al. Comprehensive registry of esophageal cancer in Japan, 2014. Esophagus. 2022;19:1–26.

Article  PubMed  Google Scholar 

Yamashita K, Watanabe M, Mine S, Fukudome I, Okamura A, Yuda M, et al. The impact of the Charlson comorbidity index on the prognosis of esophageal cancer patients who underwent esophagectomy with curative intent. Surg Today. 2018;48:632–9.

Article  PubMed  Google Scholar 

Oguma J, Ozawa S, Ishiyama K, Daiko H. Clinical significance of sarcopenic dysphagia for patients with esophageal cancer undergoing esophagectomy: A review. Ann Gastroenterol Surg. 2022;6:738–45.

Article  PubMed  PubMed Central  Google Scholar 

Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study–JCOG9204. J Clin Oncol. 2003;21:4592–6.

Article  PubMed  Google Scholar 

Yamasaki M, Yasuda T, Yano M, Hirao M, Kobayashi K, Fujitani K, et al. Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003). Ann Oncol. 2017;28:116–20.

Article  CAS  PubMed  Google Scholar 

Clavien PA, Sanabria JR, Strasberg SM. Proposed classification of complications of surgery with examples of utility in cholecystectomy. Surgery. 1992;111:518–26.

CAS  PubMed  Google Scholar 

Japan ES. Japanese Classification of esophageal cancer, 11th edition: part I. Esophagus. 2017;14:1–36.

Article  Google Scholar 

McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis. 2007;22:881–6.

Article  PubMed  Google Scholar 

Nakamura K, Kato K, Igaki H, Ito Y, Mizusawa J, Ando N, et al. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol. 2013;43:752–5.

Article  PubMed  Google Scholar 

Shiraishi O, Makino T, Yamasaki M, Tanaka K, Yamashita K, Ishida T, et al. Two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for treating locally advanced esophageal cancer: short-term outcomes of a multicenter randomized phase II trial. Esophagus. 2021;18:825–34.

Article  PubMed  Google Scholar 

Miyata H, Tanaka K, Makino T, Yamasaki M, Miyazaki Y, Takahashi T, et al. The impact of pathological tumor regression and nodal status on survival and systemic disease in patients undergoing neoadjuvant chemotherapy for esophageal squamous cell carcinoma. Ann Surg Oncol. 2018;25:2409–17.

Article  PubMed  Google Scholar 

Okamura A, Matsuda S, Mayanagi S, Kanamori J, Imamura Y, Irino T, et al. Clinical significance of pretherapeutic serum squamous cell carcinoma antigen level in patients with neoadjuvant chemotherapy for esophageal squamous cell carcinoma. Ann Surg Oncol. 2021;28:1209–16.

Article  PubMed  Google Scholar 

Hiyoshi Y, Yoshida N, Watanabe M, Kurashige J, Baba Y, Sakamoto Y, et al. The presence of serum p53 antibody predicts the pathological tumor response to neoadjuvant chemotherapy with docetaxel, cisplatin and fluorouracil (dcf) in esophageal squamous cell carcinoma. World J Surg. 2017;41:480–6.

Article  PubMed  Google Scholar 

Makino T, Yamasaki M, Miyata H, Yoshioka S, Takiguchi S, Fujiwara Y, et al. p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer. Ann Surg Oncol. 2010;17:804–11.

Article  PubMed  Google Scholar 

Yamamoto K, Makino T, Sato E, Noma T, Urakawa S, Takeoka T, et al. Tumor-infiltrating M2 macrophage in pretreatment biopsy sample predicts response to chemotherapy and survival in esophageal cancer. Cancer Sci. 2020;111:1103–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Izadi F, Sharpe BP, Breininger SP, Secrier M, Gibson J, Walker RC, et al. Genomic Analysis of Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma. Cancers (Basel). 2021; 13

Booka E, Haneda R, Ishii K, Tsushima T, Yasui H, Tsubosa Y. The negative impact of preoperative chemotherapy on survival after esophagectomy for vulnerable elderly patients with esophageal cancer. Ann Surg Oncol. 2021;28:1786–95.

Article  PubMed  Google Scholar